JFL life sciences IPO is engaged in the business of manufacturing pharmaceutical products. The company’s product portfolio consists of Dry powder injections (B-Lactam), Tablets & Capsules (B-Lactam) solid oral dosage form and Tablet and capsules (general) Solid Oral Dosage Form and Oral rehydration solutions (ORS).
JFL life sciences IPO – Overview
| IPO Dates | 25-30 Aug 2022 |
| IPO Price | INR 61 per share |
| Fresh issue | 2,978,000 shares (INR 8.17 crore) |
| Offer For Sale | Nil |
| Total IPO size | 2,978,000 shares (INR 8.17 crore) |
| Minimum bid (lot size) | 2000 shares |
| Face Value | INR 10 per share |
| Retail Allocation | 50% |
| Listing On | NSE Emerge |
JFL life sciences IPO -Tentative Dates
| IPO Offer Opening Date | 25 August 2022 |
| IPO Closing Date | 30 August 2022 |
| Finalisation of Basis of Allotment | 05 September 2022 |
| Initiation of refunds | 06 September 2022 |
| Transfer of shares to demat accounts | 07 September 2022 |
| IPO Listing Date | 08 September 2022 |
| Opening Price on NSE SME | Coming soon |
| Closing Price on NSE SME | Coming soon |
Company Overview
Incorporated in 2010, JFL Life Sciences Limited is engaged in the business of manufacturing pharmaceutical products. The company’s product portfolio consists of Dry powder injections (B-Lactam), Tablets & Capsules (B-Lactam) solid oral dosage form and Tablet and capsules (general) Solid Oral Dosage Form and Oral rehydration solutions (ORS).
The company’s sales strategy is to sell the products in bulk to pharmaceutical marketers and traders who in turn provide the channel for sales to customers. JFL Life Sciences Limited has a market presence in PAN India and JFL’s products are supplied to 10 developed and developing countries throughout the World.
JFL Life Sciences Limited exports products to African, Middle Eastern, and CIS countries, mainly through merchant exporters. The company is registered with the MOH of Kenya, Nigeria, Yemen, Cambodia & Myanmar for manufacturing a particular product. Few of our products are also registered with Ukraine, Uzbekistan, and Kazakhstan (CIS countries) through merchants.
Strengths:
- Product registration
- Experienced management and dedicated employee base
- Quality assurance
- Quality & Brand strength
Objects of the Issue
- Repayment of secured and unsecured loans.
- Funding working capital requirements.
- General corporate purposes.
Company Financials
| Particulars | 31-Feb-22 | 31-Mar-21 | 31-Mar-20 |
| Total Assets | 3662.86 | 2900.69 | 2432.59 |
| Total Revenue | 2563.06 | 3286.89 | 3020.41 |
| Profit After Tax | 253.28 | 54.21 | 36.04 |
Company Contact Information
JFL Life Sciences Limited
309, Satyam Mall,
Opp. Saman Complex, Nr. Vishweshwar Mahadev Mandir
Settelite, Ahmedabad 380015
Phone: 937729 5575
Email: cs@jfllifesciences.com
Website: http://www.jfllifesciences.com/
Registrar
KFin Technologies Limited
Phone: 04067162222, 04079611000
Email: jfl.ipo@kfintech.com
Website: https://karisma.kfintech.com/
Lead Manager(s)
- GYR Capital Advisors Limited (Past IPO Performance)
Lead Manager Reports
- IPO Lead Manager Performance Summary
- IPO Lead Manager Performance Tracker
